Literature DB >> 15242866

Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

K L Hyrich1, A J Silman, K D Watson, D P M Symmons.   

Abstract

Anti-TNFalpha therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15242866      PMCID： PMC1754871          DOI： 10.1136/ard.2004.024737

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  100 in total

1.  New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis.

Authors:  A P Cairns; M K J Duncan; A E Hinder; A J Taggart
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

2.  Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate.

Authors:  J M van der Klooster; R J Bosman; H M Oudemans-van Straaten; J I van der Spoel; J P J Wester; D F Zandstra
Journal:  Intensive Care Med       Date:  2003-11-05       Impact factor: 17.440

3.  Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis.

Authors:  Peter D Kent; John M Davis; Mark D P Davis; Eric L Matteson
Journal:  Arthritis Rheum       Date:  2002-08

4.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

5.  Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.

Authors:  William J Shergy; Reuben A Isern; David A Cooley; John L Harshbarger; J Eugene Huffstutter; Gordon M Hughes; Elizabeth A Spencer-Smith; Allan L Goldman; Sanford H Roth; J Scott Toder; Diana Warner; Adrienne Quinn; Gregory F Keenan; Thomas F Schaible
Journal:  J Rheumatol       Date:  2002-04       Impact factor: 4.666

6.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

7.  Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

Authors:  P Geborek; M Crnkic; I F Petersson; T Saxne
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

8.  [Fatal miliary tuberculosis during treatment with infliximab].

Authors:  H E Vonkeman; P D L P M van der Valk; L Mulder; M A F J van de Laar
Journal:  Ned Tijdschr Geneeskd       Date:  2002-06-22

9.  The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea.

Authors:  J E Yun; S W Lee; T H Kim; J B Jun; S Jung; S C Bae; T Y Kim; D H Yoo
Journal:  Clin Exp Rheumatol       Date:  2002 Mar-Apr       Impact factor: 4.473

10.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Vicente Rodríguez Valverde; Emilio Martín Mola; Maria Dolores Montero
Journal:  Arthritis Rheum       Date:  2003-08
View more
  38 in total

Review 1.  Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review.

Authors:  Taras Gout; Andrew J K Ostör; Muhammad K Nisar
Journal:  Clin Rheumatol       Date:  2011-08-11       Impact factor: 2.980

Review 2.  Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Authors:  Eleanor M Heather; Katherine Payne; Mark Harrison; Deborah P M Symmons
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

Review 3.  Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies.

Authors:  Silja Rott; Ulrich Mrowietz
Journal:  BMJ       Date:  2005-03-26

4.  Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment.

Authors:  Maria G Tektonidou; John Serelis; Fotini N Skopouli
Journal:  Clin Rheumatol       Date:  2006-07-06       Impact factor: 2.980

5.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 6.  Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.

Authors:  Annabel Kuek; Brian L Hazleman; Andrew J K Ostör
Journal:  Postgrad Med J       Date:  2007-04       Impact factor: 2.401

Review 7.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 8.  Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Ben A C Dijkmans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.

Authors:  Muhammad K Nisar; Aneesa Rafiq; Andrew J K Östör
Journal:  Clin Rheumatol       Date:  2015-10-24       Impact factor: 2.980

Review 10.  TNFR1 signaling kinetics: spatiotemporal control of three phases of IKK activation by posttranslational modification.

Authors:  Lauren M Workman; Hasem Habelhah
Journal:  Cell Signal       Date:  2013-04-21       Impact factor: 4.315
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.